source
- FDA approves brexu-cel CAR-T therapy for relapsed/refractory mantle cell lymphoma, highlighting safety considerationsThe U.S. Food and Drug Administration has granted approval to brexu-cel, a CAR T-cell therapy, for patients with relapsed or refractory mantle cell lymphoma (MCL). This is the first CAR T indicatio…
- CSL shares plunge to nine-year low after cutting revenue forecast and announcing $5 billion impairmentCSL's shares fell to their lowest level since early 2017 after the company reduced its full‑year revenue guidance by roughly four percent. The guidance cut signals slower sales growth than previous…Endpoints · 4mo agoEarningsNegative